Vision Mission & Strength
R & D
Niprolac Oral Sol
Starcal D Forte
NIPRO JMI Pharma Ltd. (NJP) is contributing in developing a world-class practicein the pharma industry of Bangladesh by bridling the unment challenges in healthcare sector. It is one of the fastest growing pharmaceutical companies in Bangladesh, started its journey in 2012 with collaboration of NIPRO Corporation; a Japan based giant multinational company, a press release said.
NIPRO JMI Pharma Limited (NJP) has introduced Linagliptin (Lijenta) and Empagliflozin (Empa), which are the breakthroughs in diabetic management and aiding millions of diabetic patients in the country....
NIPRO JMI Pharma Ltd. has celebrated Bangla New Year - 1426 at Corporate office....
Japan Bangladesh joint venture company- NIPRO JMI Pharma held its annual sales conference 2018 at International Convention City, Bashundhara, Dhaka.....
Rupatadine is a long-acting, non-sedative antagonist of histamine H1-receptors. It also,
antagonizes the platelet-activating factor (PAF). Both histamine and PAF causes
bronchoconstriction and lead to an increase in the vascular permeability, acting as a
mediator in the inflammatory process. This double mechanism of action gives
Rupatadine a major clinical efficacy regarding agents that show an isolated antihistamine
action. Rupatadine possesses other anti-allergic properties such as the inhibition of the
degranulation of mast cells induced by immunological and non-immunological stimuli,
and inhibition of the release of cytokines, particularly of the TNFa in human mast cells